10-K: Kiromic BioPharma's 2024 10-K Filing Reveals Ongoing Losses and Substantial Doubt About Future Viability

Kiromic BioPharma's 2024 10-K filing highlights ongoing losses, a need for additional funding, and substantial doubt about the company's ability to continue as a going concern.

Summary

• Kiromic BioPharma's 10-K filing for 2024 reveals a net loss of $26.90 million and negative cash flow from operations of $19.5 million.
• The company has an accumulated deficit of $149.8 million as of December 31, 2024.
• Kiromic BioPharma states it needs substantial additional funding to continue operations and develop its product candidates.
• The company expresses substantial doubt about its ability to continue as a going concern without securing additional financing.
• Kiromic is focusing on its Deltacel program, which is in Phase 1 clinical trials, and plans to advance Isocel and Procel programs subject to funding.
• The company is seeking short-term financing to continue operations and is working with a financial advisor.
• Kiromic is exploring cost reduction measures, including workforce reductions and delaying research and development expenditures.
• The company is also seeking to relist on a major stock exchange to increase liquidity.
• As of January 31, 2025, Kiromic had $1.48 million in cash and cash equivalents, including $659 thousand of restricted cash.
• The first patient in the Deltacel-01 trial received treatment in December 2023, and ten patients have been enrolled as of January 2025.
• The company has registered a 6-month median Progression Free Survival (PFS) with a median length of follow-up of over 10 months and the longest PFS of 12 months in the Deltacel-01 trial.
• Kiromic submitted an IND protocol amendment to the FDA in October 2024 to improve the therapeutic approach.
• Depending on the response rates in the Deltacel-01 trial, Kiromic may initiate a pivotal Phase 2 trial in the second half of 2025.
• The company is building an intellectual property portfolio around its product candidates and discovery programs.
• Kiromic faces competition in the solid tumor therapies market from various biopharmaceutical companies.
• The company is subject to extensive government regulations, including FDA requirements for biological products.
• Kiromic is an emerging growth company and may take advantage of exemptions from certain reporting requirements.
• The company is subject to securities laws claims regarding past disclosures and has reached a settlement in principle for a class action lawsuit.
• Kiromic is also subject to risks associated with increased political uncertainty, including the conflict in Ukraine.
• The company is dependent on third parties for the supply of biological materials and the manufacture of product supplies.
• Kiromic is subject to data privacy and security regulations, including HIPAA, GDPR, and CCPA.
• The company had 44 employees as of December 31, 2024.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with ongoing losses and a going concern warning, offset slightly by clinical trial progress. The need for additional funding and potential cost-cutting measures contribute to a negative outlook.

Positives

• Deltacel has shown promising survival benefits in the absence of limiting toxicities, leading to the activation of the expansion phase in September 2024.
• The company has registered a 6-month median Progression Free Survival (PFS) with a median length of follow-up of over 10 months and the longest PFS of 12 months in the Deltacel-01 trial.
• Kiromic submitted an IND protocol amendment to the FDA in October 2024 to improve the therapeutic approach.
• The company is building an intellectual property portfolio around its product candidates and discovery programs.
• Kiromic is an emerging growth company and may take advantage of exemptions from certain reporting requirements.
• The company has finalized a settlement with the SEC, resolving the investigation without a civil penalty.

Negatives

• Kiromic BioPharma's 2024 10-K filing reveals a net loss of $26.90 million and negative cash flow from operations of $19.5 million.
• The company has an accumulated deficit of $149.8 million as of December 31, 2024.
• Kiromic BioPharma states it needs substantial additional funding to continue operations and develop its product candidates.
• The company expresses substantial doubt about its ability to continue as a going concern without securing additional financing.
• As of January 31, 2025, Kiromic had $1.48 million in cash and cash equivalents, including $659 thousand of restricted cash.

Risks

• The company expresses substantial doubt about its ability to continue as a going concern without securing additional financing.
• Kiromic faces substantial competition from other pharmaceutical and biotechnology companies.
• The company is dependent on third parties for the supply of biological materials and the manufacture of product supplies.
• Kiromic is subject to data privacy and security regulations, including HIPAA, GDPR, and CCPA.
• The company is subject to securities laws claims regarding past disclosures and has reached a settlement in principle for a class action lawsuit.
• The company is subject to risks associated with increased political uncertainty, including the conflict in Ukraine.

Future Outlook

The company plans to continue the development of Isocel and Procel once it gathers sufficient financial support and may initiate a pivotal Phase 2 trial in the second half of 2025 depending on the response rates in the Deltacel-01 Phase 1 clinical trial.

Industry Context

The document notes that the global T cell therapy market is expected to grow to over $33B by 2027, and that Kiromic is positioned to address the solid tumor market, which represents approximately 90% of new cancer cases.

Comparison to Industry Standards

• The document mentions several competitors in the allogeneic cell therapy space, including Fate Therapeutics, Poseida Therapeutics, Allogene Therapeutics, Adicet Bio, Inc., Cytomed Therapeutics, IN8 Bio, Inc., TC Biopharm Limited, and GammaDelta Therapeutics Limited (acquired by Takeda).
• It states that Kiromic believes it is unique in its position to target multiple solid malignancies with a combination of non-engineered and engineered, but not gene-edited, allogeneic off-the-shelf GDT cells and to be the first to use an innovative low-dose radiation protocol in combination with its cell products.

Legal Proceedings

• The company is involved in ongoing litigation related to the Jason Terrell claim, which has been remanded to the Chancery Court for further proceedings.
• The company has reached a settlement in principle for the Karp and Podmore class action lawsuit and has paid the settlement amount into an escrow account.
• The company finalized a settlement with the SEC, resolving the investigation without a civil penalty.

Stakeholder Impact

• Shareholders face the risk of dilution if the company issues additional shares of capital stock.
• Shareholders may experience substantial dilution in the value of their investment if the company issues additional shares of its capital stock, including in connection with the sale or issuance of its common stock.
• Employees may be affected by potential cost reduction measures, including workforce reductions.
• The company's ability to continue as a going concern impacts its ability to meet its obligations to suppliers and creditors.
• Patients may be affected by delays or discontinuation of clinical trials due to financial constraints.

Next Steps

• Continue the Deltacel-01 Phase 1 clinical trial and enroll additional patients.
• Submit the Isocel IND in the second half of 2025, and the Procel IND in the second quarter of 2026, subject to sufficient financing.
• Seek feedback from the FDA regarding the design of the pivotal Phase 2 trial for Deltacel around June 2025.
• Potentially initiate a Phase 2 trial for Deltacel before the end of 2025.
• Seek Breakthrough Therapy Designation (BTD) for Deltacel in the second half of 2025.
• Seek short-term financing to continue operations and fund other liquidity needs.

Key Dates

Keywords

Kiromic BioPharma, Deltacel, Isocel, Procel, clinical trials, funding, biopharmaceutical, immunotherapy, going concern, FDA, research and development, losses